NEW YORK (GenomeWeb News) — Epidauros and InPheno earlier this week said they plan to co-market their pharmacogenomic and phenotypic services to drug developers as a single service.
“We are trying to bring both genotype and phenotype analysis together because genetic analysis alone is not sufficient to predict statistical variance in clinical outcomes,” Hans Peter Arnold, director of business development and marketing at Epidauros, told GenomeWeb News this week.
The partnership could begin with marketing HIV services. InPheno already has an HIV analysis service, and Arnold said Epidauros expects to expand in that direction.
Epidauros CEO Michael Lutz said that adding InPheno’s capabilities in virology, oncology, and other diseases counts as an “important expansion” of the company’s clinical genotyping services.
Financial terms of the agreement were not released.